Cencora (COR) came out with quarterly earnings of $3.80 per share, beating the Zacks Consensus Estimate of $3.65 per share. This compares to earnings of $3.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.11%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $2.86 per share when it actually produced earnings of $3.28, delivering a surprise of 14.69%.Over the last four quarters, ...

• Interest Expense, Net: No adjustments were made to the GAAP presentation of net interest expense. In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter. Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt. The increase in interest expense was offset by the increase in in ...

Wall Street analysts forecast that Cencora (COR) will report quarterly earnings of $3.65 per share in its upcoming release, pointing to a year-over-year increase of 4.3%. It is anticipated that revenues will amount to $70.35 billion, exhibiting an increase of 10.9% compared to the year-ago quarter.Over the last 30 days, there has been a downward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of th ...

Every portfolio needs a solid foundation of high-quality stocks that can provide steady returns through all market environments. While I often discuss more speculative growth and penny stock plays in my articles that some view as high-risk, high-reward bets, the core of your portfolio should revolve around a select few tried-and-true companies. We all know the big tech giants and other household names that seem to keep climbing higher. But today, I want to look beyond those ubiquitous stocks and highlight t ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style ...

Shares of Cencora (COR) have been strong performers lately, with the stock up 4.7% over the past month. The stock hit a new 52-week high of $246.75 in the previous session. Cencora has gained 19.7% since the start of the year compared to the 5.9% move for the Zacks Medical sector and the 5.6% return for the Zacks Medical Services industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the las ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed a ...

The Medical Services sector is evolving at a rapid pace. The pandemic years reshaped the market dynamics within this sector in a profound way and on a permanent basis. The need for remote monitoring and distant treatment has paved the way for digital services. Even though the pandemic has ended, digital healthcare treatment continues to be indispensable, backed by the adoption of data and analytics. Telemedicine-focused online medical and AI-powered technology services, which flourished during the pandemic, ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed a ...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that Steven H. Collis will retire as President and Chief Executive Officer of the Company and transition to the role of Executive Chair of the Cencora Board of Directors, effective October 1, 2024. Robert P. Mauch, PharmD, PhD, current Chief Operating Officer of Cencora, will succeed Collis as President and CEO, and will also be appointed as a member of the Company's Board, effective the same date. “Steve’s 30-year career at Ce ...